Experience with the DMPA injectable contraceptive: Findings from a survey of DMPA acceptors

This report presents the results of a survey of 899 DMPA acceptors who availed of injectable contraceptive services from public health facilities under the Philippine Department of Health\u27s (DOH) DMPA Reintroduction Program. The survey is part of the DMPA Monitoring and Follow-up Studies sponsored by the Population Council’s Manila office in response to a request by the DOH to provide operations research support to the program. Depot-medroxyprogesterone acetate (DMPA), commonly known as Depo-Provera, is a three-month injectable contraceptive. It was recently officially endorsed as a family planning (FP) program method by the DOH, following its approval by the Philippine Bureau of Food and Drugs in November 1993. DMPA as a program method was launched by the DOH in April 1994 in six provinces and four chartered cities spread throughout seven administrative regions in the Philippines. The program aims to reintroduce DMPA into the Philippine Family Planning Program via the training of local-level midwives, nurses, and doctors as DMPA service providers, and by the provision of free DMPA services in selected public health facilities nationwide

Knowledge, attitudes and practice of the DMPA injectable contraceptive: Data from focus group discussions

This report is based on data from 12 focus group discussions conducted throughout the Philippines as part of the DMPA Monitoring and Follow-up Studies. The DMPA Monitoring and Follow-up Studies are part of a technical assistance project undertaken by the Population Council in support of the Department of Health’s DMPA Reintroduction Program. The project provides data on DMPA (depot-medroxyprogesterone acetate) acceptance and continuation rates as well profiles of DMPA users and dropouts to serve as bases for decisions and policies that will ensure quality services. The project draws information from several sources including a 15-month monitoring of DMPA acceptors; surveys of DMPA users and dropouts; focus group discussions with DMPA dropouts, nonusers, and husbands of DMPA users; and interviews with DMPA service providers. This report focuses on the results of the focus group discussions among DMPA dropouts, nonusers, and husbands of DMPA users. The DMPA Reintroduction Program was initiated by the DOH in 1994, following the approval of use of DMPA by the Philippine Bureau of Food and Drugs in 1993. The program aims to reintroduce DMPA into the Philippine Family Planning Program

The DMPA service provider: Profile, problems and prospects, August 1995

This report presents the results of interviews conducted with 60 trained DMPA service providers from seven of the ten local government units (LGUs) covered by Phase I of the Philippine Department of Health\u27s DMPA Reintroduction Program. DMPA, or Depot-medroxyprogesterone acetate, is an injectable contraceptive commonly known as Depo-Provera. The interviews were undertaken as part of the DMPA Monitoring and Follow-up Studies sponsored by the Population Council under the Asia and Near East Operations Research and Technical Assistance (ANE OR/TA) Project. While the monitoring study and the follow-up survey focused on DMPA users and dropouts, this study centered on the service provider. The DMPA Reintroduction Program was launched by the DOH in April 1994 by the Philippine Bureau of Food and Drugs. The program aims to reintroduce DMPA into the Philippine Family Planning Program through training local-level doctors, nurses, and midwives as service providers, and providing free DMPA services in selected public health facilities